Effective regulatory pathways and approval processes balance the urgency of public health needs with rigorous safety and efficacy standards. National and international agencies evaluate data across clinical phases to authorize vaccines for emergency or general use. Conditional approvals, rolling submissions, and priority reviews have become more common, particularly in response to pandemics. Clear guidance on dossier requirements, manufacturing practices, and pharmacovigilance expectations helps streamline developer timelines. Regulatory pathways and approval processes must remain adaptable to new technologies like personalized vaccines and nanocarrier systems. Global harmonization efforts, such as reliance models and mutual recognition agreements, are enabling faster cross-border access. Transparent, science-based regulation fosters trust, accelerates innovation, and ensures public confidence in immunization programs.
Khursheed Anwer
IMUNON, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Khursheed Anwer
IMUNON, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Lara Isis Teodoro
Mayo Clinic, United States
Ahmed Abdulazeez
BHRUT Trust, United Kingdom
Elena Chiappini
University of Florence, ItalySubmit your abstract Today
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology Analysis of MPXV and VACV Peptides Underscores the Need to Consider Both MPXV Clades for Vaccine Development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Immunogenicity and Cryo-EM structure of native-like HIV-1 Clade-C envelope trimers derived from a pediatric elite-neutralizer
Swarandeep Singh, All India Institute of Medical Sciences, India
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Awareness and acceptability of rotavirus vaccine among mothers of under-five children in Gusau and Bungudu communities of Zamfara state, northwestern Nigeria
Attahir Abubakar, Ahmadu Bello University, Nigeria
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil